Analyst Price Target is $26.50
▲ +145.60% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Terns Pharmaceuticals in the last 3 months. The average price target is $26.50, with a high forecast of $32.00 and a low forecast of $21.00. The average price target represents a 145.60% upside from the last price of $10.79.
Current Consensus is
The current consensus among 3 contributing investment analysts is to buy stock in Terns Pharmaceuticals.
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. It develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase I clinical trial for the treatment of NASH. The company also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and GLP-1R, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to address metabolic processes involved in the pathogenesis of NASH. Terns Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Foster City, California.